Q2 2025 Tenon Medical Inc Earnings Call Transcript
Key Points
- Tenon Medical Inc (TNON) completed a strategic acquisition of CyVantage, enhancing their commercial organization and unlocking new market pathways.
- The integration of CyVantage is expected to deliver active case value and revenue-generating technologies, scaling the company's operations.
- The Catamaran SE, a second-generation low-profile implant, is on track for a full commercial launch, receiving favorable feedback.
- Tenon Medical Inc (TNON) reduced operating expenses by 29% year over year, demonstrating financial discipline while preserving growth investments.
- The company ended the quarter with $7.8 million in cash and no debt, providing flexibility to execute their strategic roadmap.
- Revenue for the second quarter of 2025 was $564,000, a decline from $901,000 in the same period last year.
- Gross profit decreased to $245,000 or 43% of revenue, compared to $470,000 or 52% of revenue in the prior year quarter.
- The decline in revenue was attributed to lower procedure volumes and account mix headwinds, driven by a strategic shift in commercial initiatives.
- Net loss for the second quarter was $2.8 million, although improved from a net loss of $3.8 million in the second quarter of 2024.
- The company experienced a temporary disruption in sales personnel and commercial activities due to the focus on the CyVantage acquisition.
Greetings and welcome to the Tenon 2nd quarter 2025 earnings conference call. At this time, and only mode. A brief question and answer session will follow the formal presentation. If anyone should require operators' assistance during the conference, please press 0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host Steven M. Foster, CEO and President.
Thank you. You may begin.
Thank you, Maria, and good afternoon, everyone. I'm pleased to welcome you to today's 2nd quarter of 2025 financial results and corporate update conference call for Tenon Medical Inc.
We recently marked a pivotal step forward for Tenon Medical, highlighted by a strategic acquisition on top of a 2nd quarter that included continued clinical validation and meaningful progress towards diversification of our product offering.
Speaking to our recent announcement, a significant focus of our 2nd quarter initiatives was the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
